Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100

Benzinga · 4d ago
Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $103 to $100.